Career records & work history
Medicine Doctors
Aimin Zhang
Specialties:
Occupational Medicine
Aimin Te Zhang, 49Hayward, CA
Aimin Zhang Phones & Addresses
Castro Valley, CA
San Leandro, CA
Buffalo, NY
Amherst, NY
Chicago, IL
Alameda, CA
Mentions for Aimin Te Zhang
Publications & IP owners
Us Patents
Phosphorus Containing Quinazoline Compounds And Methods Of Use
US Patent:
2012019, Aug 2, 2012
Filed:
Jul 2, 2010
Appl. No.:
13/380808
Inventors:
Wang Shen - San Mateo CA, US
Aimin Zhang - Castro Valley CA, US
Junfa Fan - Hayward CA, US
Xiaoling Zheng - Fremont CA, US
Aimin Zhang - Castro Valley CA, US
Junfa Fan - Hayward CA, US
Xiaoling Zheng - Fremont CA, US
International Classification:
A61K 31/675
A61P 35/00
C07F 9/6571
C07F 9/6584
C07F 9/655
A61P 35/00
C07F 9/6571
C07F 9/6584
C07F 9/655
US Classification:
514 80, 544244
Abstract:
Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.
Tricyclic Inhibitors Of Poly(Adp-Ribose)Polymerase
US Patent:
2023002, Jan 26, 2023
Filed:
Feb 14, 2022
Appl. No.:
17/671436
Inventors:
- Vancouver, CA
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07F 9/6584
Abstract:
The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Alkyne Substituted Quinazoline Compound And Methods Of Use
US Patent:
2021004, Feb 18, 2021
Filed:
Mar 27, 2020
Appl. No.:
16/833020
Inventors:
- Menlo Park CA, US
Aimin ZHANG - Castro Valley CA, US
Jack MAUNG - Daly City CA, US
Xiaoling ZHENG - Fremont CA, US
Aimin ZHANG - Castro Valley CA, US
Jack MAUNG - Daly City CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07D 405/06
A61K 31/517
A61K 31/517
Abstract:
The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Tricyclic Inhibitors Of Poly(Adp-Ribose)Polymerase
US Patent:
2020029, Sep 24, 2020
Filed:
Oct 28, 2019
Appl. No.:
16/666307
Inventors:
- Menlo Park CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07F 9/6584
Abstract:
The invention provides lor compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds arc potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Alkyne Substituted Quinazoline Compound And Methods Of Use
US Patent:
2019038, Dec 19, 2019
Filed:
Jan 18, 2019
Appl. No.:
16/252458
Inventors:
- Menlo Park CA, US
Aimin ZHANG - Castro Valley CA, US
Jack MAUNG - Daly City CA, US
Xiaoling ZHENG - Fremont CA, US
Aimin ZHANG - Castro Valley CA, US
Jack MAUNG - Daly City CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07D 405/06
A61K 31/517
A61K 31/517
Abstract:
The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Alkyne Substituted Quinazoline Compound And Methods Of Use
US Patent:
2018009, Apr 5, 2018
Filed:
Aug 11, 2017
Appl. No.:
15/675438
Inventors:
- Menlo Park CA, US
Aimin ZHANG - Castro Valley CA, US
Jack MAUNG - Daly City CA, US
Xiaoling ZHENG - Fremont CA, US
Aimin ZHANG - Castro Valley CA, US
Jack MAUNG - Daly City CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07D 405/06
A61K 31/517
A61K 31/517
Abstract:
The invention provides alkyne substituted quinazoline compounds, such as compounds of the formula (I), which are irreversible ErbB kinase inhibitors. The compounds are useful in the treatment of diseases and disorders where ErbB kinase activity is implicated such as a hyperproliferative disorder (e.g., cancer).
Tricyclic Inhibitors Of Poly(Adp-Ribose)Polymerase
US Patent:
2018009, Apr 5, 2018
Filed:
Jun 15, 2017
Appl. No.:
15/624201
Inventors:
- Menlo Park CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07F 9/6584
Abstract:
The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Tricyclic Inhibitors Of Poly(Adp-Ribose)Polymerase
US Patent:
2017005, Mar 2, 2017
Filed:
Apr 1, 2016
Appl. No.:
15/089131
Inventors:
- Menlo Park CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
Jack MAUNG - Daly City CA, US
Aimin ZHANG - Castro Valley CA, US
Xiaoling ZHENG - Fremont CA, US
International Classification:
C07F 9/6584
Abstract:
The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Possible Relatives
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.